HIGHLIGHTS
- who: Jian Wu and collaborators from the Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical have published the article: PIM Kinases in Multiple Myeloma, in the Journal: Cancers 2021, 4304 of /2021/
- what: This study showed that PIM447 in combination with the standard treatment pomalidomide + dexamethasone exerts a potent antitumor effect and significantly improves survival with respect to the standard treatment.
- future: PIM447 250 mg or 300 mg QD was tolerated in Japanese patients with R/R MM. Further studies are required to evaluate clinical outcomes of PIM447 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.